# Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

> **NCT00004786** · PHASE3 · COMPLETED · sponsor: **National Center for Research Resources (NCRR)** · enrollment: 200 (—)

## Conditions studied

- Systemic Sclerosis
- Raynaud Disease

## Interventions

- **DRUG:** iloprost

## Key facts

- **NCT ID:** NCT00004786
- **Lead sponsor:** National Center for Research Resources (NCRR)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004786, "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00004786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*